|
[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424.
|
|
[2] CHOI KJ,BAIK IH,YE SK,et al. Molecular targeted therapy for hepatocellular carcinoma:Present status and future directions[J]. Biol Pharm Bull,2015,38(7):986-991.
|
|
[3] CHENG A,KANG Y,CHEN Z,et al. Randomized phaseⅢtrial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma[J]. J Clin Oncol,2008,26(20Suppl):4509.
|
|
[4] PALMER DH. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med,2008,359(23):2498; author reply 2498-2499.
|
|
[5] SUN B,YANG XZ,XIE F,et al. Effect of sorafenib combined with transcatheter arterial chemoembolization and radiofrequency ablation on the survival of patients with hepatocellular carcinoma[J]. J Clin Hepatol,2019,35(1):104-108.
|
|
[6] BRUIX J,QIN S,MERLE P,et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment(RESORCE):A randomised,double-blind,placebo-control ed,phase 3 trial[J]. Lancet,2017,389(10064):56-66.
|
|
[7] FINN RS,MERLE P,GRANITO A,et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC:Additional analyses from the phase III RESORCE trial[J]. J Hepatol,2018,69(2):353-358.
|
|
[8] SHLOMAI A,LESHNO M,GOLDSTEIN DA. Regorafenib treatment for patients with hepatocellular carcinoma who progressed on sorafenib-A cost-effectiveness analysis[J].PLo S One,2018,13(11):e0207132.
|
|
[9] CUI YL. Targeted therapy for hepatocellular carcinoma[J].Chin J Dig Surg,2018,17(5):445-451.(in Chinese)崔云龙．肝癌的靶向治疗[J]．中华消化外科杂志，2018,17(5):445-451.
|
|
[10] YAMAMOTO Y,MATSUI J,MATSUSHIMA T,et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR,shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage[J]. Vasc Cell,2014,6:18.
|
|
[11] KUDO M,FINN RS,QIN S,et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:A randomised phase 3 non-inferiority trial[J]. Lancet,2018,391(10126):1163-1173.
|
|
[12] KUDO M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma[J]. Liver Cancer,2018,7(1):1-19.
|
|
[13] Chen SC,CHAO Y,CHEN MH,et al. Lenvatinib for the treatment of HCC:A single institute experience[J]. J Clin Oncol,2019,37(Suppl 15):e15611.
|
|
[14] CHANG QQ,PENG Y,WANG GJ,et al. Clinical research progress of small molecule tyrosine kinase inhibitors against hepatocellular carcinoma[J]. Chin J Clin Pharmacol Ther,2019,24(8):948-956.(in Chinese)常青青，彭英，王广基，等．抗肝癌小分子酪氨酸激酶抑制剂的临床研究进展[J]．中国临床药理学与治疗学，2019,24(8):948-956.
|
|
[15] ELISEI R,SCHLUMBERGER MJ,MULLER SP,et al. Cabozantinib in progressive medullary thyroid cancer[J]. J Clin Oncol,2013,31(29):3639-3646.
|
|
[16] ABOU-ALFA GK,MEYER T,CHENG AL,et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med,2018,379(1):54-63.
|
|
[17] KUDO M. Cabozantinib as a second-line agent in advanced hepatocellular carcinoma[J]. Liver Cancer,2018,7(2):123-133.
|
|
[18] QIN SK,BAI YX,OUYANG XN,et al. Apatinib for patients with advanced hepatocellular carcinoma:A randomised,open-label,multicentre,phaseⅡclinical trial[J]. Chin Clin Oncol,2017,22(12):1057-1065.(in Chinese)秦叔逵，白玉贤，欧阳学农，等．阿帕替尼一线治疗晚期肝细胞癌的前瞻性、随机、开放、全国多中心Ⅱ期临床试验[J]．临床肿瘤学杂志，2017,22(12):1057-1065.
|
|
[19] WU J,YIN F,LUO GH,et al. Clinical effect and safety of transarterial chemoembolization combined with apatinib in treatment of advanced primary liver cancer[J]. J Clin Hepatol,2018,34(4):775-778.
|
|
[20] THOMAS MB,GARRETT-MAYER E,ANIS M,et al. A randomized phase II open-label multi-institution study of the combination of bevacizumab and erlotinib compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma[J]. Oncology,2018,94(6):329-339.
|
|
[21] HE L,DENG H,LEI J,et al. Efficacy of bevacizumab combined with erlotinib for advanced hepatocellular carcinoma:A single-arm meta-analysis based on prospective studies[J]. BMC Cancer,2019,19(1):276.
|
|
[22] ZHU AX,PARK JO,RYOO BY,et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib(REACH):A randomised,double-blind,multicentre,phase 3 trial[J]. Lancet Oncol,2015,16(7):859-870.
|
|
[23] ZHU AX,KANG YK,YEN CJ,et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations(REACH-2):A randomised,double-blind,placebo-controlled,phase 3 trial[J]. Lancet Oncol,2019,20(2):282-296.
|
|
[24] ZHU AX,KUDO M,ASSENAT E,et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib:The EVOLVE-1 randomized clinical trial[J]. Jama,2014,312(1):57-67.
|
|
[25] CHOLONGITAS E,ANTONIADIS N,GOULIS I,et al. Trough levels of everolimus are associated with recurrence rates of hepatocellular carcinoma after liver transplantation[J]. Transplant Proc,2019,51(2):450-453.
|
|
[26] SANGRO B,GOMEZ-MARTIN C,de la MATA M,et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C[J]. J Hepatol,2013,59(1):81-88.
|
|
[27] QIN SK,REN ZG,MENG ZQ,et al. A randomized multicentered phase II study to evaluate SHR-1210(PD-1 antibody)in subjects with advanced hepatocellular carcinoma(HCC)who failed or intolerable to prior systemic treatment[J]. Ann Oncol,2018,29(8):2.
|
|
[28] CONTRATTO M,WU J. Targeted therapy or immunotherapy?Optimal treatment in hepatocellular carcinoma[J]. World J Gastrointest Oncol,2018,10(5):108-114.
|
|
[29] EL-KHOUEIRY AB,SANGRO B,YAU T,et al. Nivolumab in patients with advanced hepatocellular carcinoma(CheckMate040):An open-label,non-comparative,phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088):2492-2502.
|
|
[30] EL-KHOUEIRY AB,MELERO I,YAU TC,et al. Impact of antitumor activity on survival outcomes, and nonconventional benefit,with nivolumab(NIVO)in patients with advanced hepatocellular carcinoma(a HCC):Subanalyses of CheckMate-040[J]. J Clin Oncol,2018,36(4suppl):475.
|
|
[31] KUDO M,MATILLA A,SANTORO A,et al. Checkmate-040:Nivolumab(NIVO)in patients(pts)with advanced hepatocellular carcinoma(a HCC)and Child-Pugh B(CPB)status[J]. J Clin Oncol,2019,37(4suppl):327.
|
|
[32] ZHU AX,FINN RS,EDELINE J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE-224):A non-randomised,open-label phase 2 trial[J]. Lancet Oncol,2018,19(7):940-952.
|
|
[33] ABOU-ALFA GK,QIN S,RYOO BY,et al. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma[J]. Ann Oncol,2018,29(6):1402-1408.
|
|
[34] IKEDA M,KOBAYASHI M,TAHARA M,et al. Optimal management of patients with hepatocellular carcinoma treated with lenvatinib[J]. Expert Opin Drug Saf,2018,17(11):1095-1105.
|
|
[35] IKEDA M,SUNG MW,KUDO M,et al. A phase 1b trial of lenvatinib(LEN)plus pembrolizumab(PEM)in patients(pts)with unresectable hepatocellular carcinoma(u HCC)[J]. J Clin Oncol,2018,36(15suppl):4076-4076.
|
|
[36] IKEDA M,SUNG MW,KUDO M,et al. A phase Ib trial of lenvatinib(LEN)plus pembrolizumab(PEMBRO)in unresectable hepatocellular carcinoma(u HCC):Updated results[R].2019 AACR,CT061/18.
|
DownLoad: